Preveceutical Medical Inc · CSE:PREV
Preveceutical Medical — BioGene Therapeutics — Investor Presentation (June 2026)
41 slides from Preveceutical Medical's investor presentation, Jun 12, 2026
Slide 1: Investor Presentation Q2 2026
Q2 - 2026 Investor Presentation biogenetherapeutics. com 1
Slide 2: Our Mission
Our Mission BioGene commits to Delivering the Future of Genetic Medicines with Precision Delivery, opening the door to alternative patient-friendly routes of LNP administration through innovative products and platforms that target key tissues of interest in obesity and diabetes…and beyond! biogeneth
Slide 3: Our Vision
Our Vision Our vision is to deliver safe, effective, patient -friendly curative therapies for metabolic disorders that restore normal metabolic function involved in glucose regulation and fat metabolism. biogenetherapeutics. com 3 32 2
Slide 4: Board of Directors
Board of Directors Stephen Van Deventer Deepak Sampath, PhD Steve Glover Stephen is the Deepak serves as an Steve serves as a Chairman, CEO and Independent Director Board Member for President of BioGene for BioGene. He is the BioGene, bringing Therapeutics Inc. and Senior VP, Head of multifaceted Pr
Slide 5: Board of Directors
Board of Directors Patroski J. Lawson, MSP Raj Pruthi, MD, MHA, FACS Ty Howton Patroski is the founder Raj serves BioGene as Ty serves as an and CEO of KPM an Independent Independent Director Group DC, a strategic Director. He has over of BioGene public affairs firm. He 20 years experience Therapeut
Slide 6: Senior Management
Senior Management Stephen Van Deventer Alex McAuly, CPA Harry Parekh, PhD Francis Tavares, PhD Kamal Albarazanji Stephen is the Alex serves as the Harry is Chief Science Francis serves as Chief Kamal is Senior Chairman, CEO and Chief Financial Officer & Scientific Technology Officer of Director of M
Slide 7: Corporate Advisory Board
Corporate Advisory Board Steve Glover Stephen Van Deventer Deepak Sampath, PhD Brian Gallagher, Jr. Kathy Rokita Steve acts the Stephen serves on the Deepak serves on Brian sits on the Kathy joins the Chairman of the Corporate Advisory BioGene’s Corporate Corporate Advisory Corporate Advisory Corpor
Slide 8: Scientific Advisory Board
Scientific Advisory Board Deepak Sampath, PhD Prof. Mirela Delibegović Barry Ticho, MD, PhD Francis Tavares, PhD Kamal Albarazanji Deepak serves as As a member of Barry serves on Francis sits on the Kamal sits on the Chairman of BioGene’s BioGene’s Scientific BioGene’s Scientific Scientific Advisory
Slide 9: Senior Research Team
Senior Research Team Rink-Jan Lohman, PhD Preeti Pandey, PhD Karnaker Tupally, PhD Dr Lohman is a Dr. Pandey is a highly Dr Tupally is an professional pharmo- proficient accomplished toxicologist with over pharmaceutical formulation and 20 years of experience product development bioanalytical scient
Slide 10: BioGene Australia
BIOGENE AUSTRALIA BioGene has established a wholly-owned subsidiary in Brisbane, Queensland, Australia. Bolster R&D activities and provide significant R&D Formulation & Preclinical Facility cash-back on R&D from the Australian government. Brisbane BioGene is eligible to receive 43.5% cash back from
Slide 11: Problem
Problem OBESITY 1 Cases have tripled in the past decade leading to elevated risk of mortality: heart disease, stroke and dementia. DIABETES 2 1 in 10 adults are diagnosed with diabetes. Childhood rates of diabetes & obesity are on a steep upward trajectory. DRUG SIDE EFFECTS 3 Debilitating and even
Slide 12: Obesity Rates and Diabetes Rates
Obesity Rates Diabetes rates 1 -in-10 Adults are Diabetic with Obesity Cases Triple in a Decade Child Cases Rapidly Rising • The World Obesity Federation (WOF) predicts • Leads to >4 million adult deaths a year. the economic impact of obesity will reach >US$4 trillion annually by 2035. • Over 570 mi
Slide 13: GLP1 agonists changed treatment but unmet needs remain
GLP1 agonist have changed the obesity treatment paradigm but significant unmet medical needs remain Present with an array of issues: • Severe sometimes life-threatening side effects Muscle Loss Is • 40% of patients stop treatment by one year Significant • 20-40% muscle loss • Patients build toleranc
Slide 14: The Obesity Landscape is Rapidly Evolving into Next Generation Therapies
The Obesity Landscape is Rapidly Evolving into Next Generation Therapies biogenetherapeutics. com 14
Slide 15: Landscape of Nucleic Acid Therapeutics for Obesity Treatment
Landscape of Nucleic Acid Therapeutics for Obesity Treatment siRNA Companies Alnylam Pharmaceuticals (NASDAQ: ALNY) •Program: ALN-APP (targeting amyloid precursor protein in the CNS) and other metabolic disease candidates •Technology: Proprietary siRNA platform, with success in multiple therapeutic
Slide 16: BioGene's A-to-Z solution
BioGene’s A-to-Z solution Dual gene therapy siRNAs targeting obesity and diabetes -> restore metabolic function with reduced side effects, increased compliance and cost-effectiveness SOL-GEL BIORESPONSIVE DUAL GENE Smart-siRNA's PLATFORM LNP PLATFORM THERAPY Bioresponsive self- Metabolically- A vers
Slide 17: SOL-GEL Nose-To-Brain Platform Delivery
SOL-GEL Nose-To-Brain Platform Delivery Direct Nose-to-Brain Delivery Challenges with Oral The Blood-Brain-Barrier Olfactory Pathway Delivery Route Targeting with Sol-Gel Desired patient outcomes are BBB remains a universal achieved by consistent and Rapid breakdown by hurdle for drugs intended for
Slide 18: What is the Sol-Gel Platform?
What is the Sol-Gel Platform? A solution that is engineered to rapidly gel upon contact with mucosa… • Targeted spray (‘sol’) delivery and retention (‘gel’) on mucosa • Controlled and sustained release (nanomicellar-formulation) to and through mucosa Ambient Temperature Nasal Cavity Temperature temp
Slide 19: Conventional nasal spray delivery intranasally
Conventional nasal spray delivery intranasally Nasal sprays deliver formulation throughout the nasal cavity, and are rapidly cleared… • Anterior & posterior leakage • Rapid ciliary clearance • Poor retention • Unpredictable transmucosal delivery to trigeminal nerves biogenetherapeutics. com 19
Slide 20: Sol-Gel Platform Technology & Device
Sol-Gel Platform Technology & Device Olfactory mucosa targeting, rapid sol-to-gel transition, muco-retention and sustained delivery • Exclusive olfactory targeting • Direct, rapid nose-to-brain delivery • Mucoadhesive sol-gel provides for sustained & controlled delivery • Patient-friendly water or b
Slide 21: PoC study using N2B sol-gel for treatment refractive psychosis
PoC study using N2B sol-gel for treatment refractive psychosis… Clozapine: Clozapine: Peripheral The ‘Gold Side Standard’ EffectsAnti-Psychotic Drug (APD) ACTIONS WORST SIDE EFFECTS ↓ Suicidality Myocarditis / Cardiomyopathy ↓ Hallucinations & delusions Metabolic Syndrome ↓ Risk of EPS OBESITY T2DM
Slide 22: PoC study confirms N2B sol-gel brain-biased delivery
PoC study confirms N2B sol-gel brain-biased delivery for treatment refractive psychosis…Published in *Translational Psychiatry (2026)* • Clozapine is exemplary in alleviating positive & negative ve symptoms of psychosis, but is plagued with serious, debilitating peripheral side effects, limiting it’
Slide 23: PoC study confirms N2B sol-gel is efficacious
PoC study confirms N2B sol-gel is efficacious for treatment refractive psychosis… Clozapine anti-psychotic drug action - daily dosing for 7 days (acute study) Acute Oral Acute Intranasal 100 100 80 80 % CAR 60 60 This is 28-fold 40 Control 40 Control lower than Clozapine Clozapine the oral 20 250 mi
Slide 24: BioGene's Solution for Next Generation Diabetes and Obesity Therapeutics
BioGene’s Solution for Next Generation Diabetes and Obesity Therapeutics Dual gene therapy siRNAs targeting obesity and diabetes -> restore metabolic function with reduced side effects, increased compliance and cost-effectiveness SOL-GEL BIORESPONSIVE DUAL GENE Smart-siRNA's PLATFORM LNP PLATFORM TH
Slide 25: Non-Viral Vector Platform - Bioresponsive LNPs (bLNP)
Non-Viral Vector Platform - BioGene’s Bioresponsive LNPs (bLNP) • Next generation – non-viral bioresponsive vector • US Patent # 11,566,044 granted, 31st March 2023 Comprehensive release of all genetic cargo from their carrier… Significant implications for precision medicine in mainstream disease re
Slide 26: PTP1B Validation in Diabetes & Obesity
PTP1B Validation in Diabetes(insulin resistance) & Obesity(leptin signaling) PTP1B directly dephopshorylates the Insulin Receptor while indirectly acting on the leptin receptor to regulate satiety through Jak2/Stat3. Dual therapy approach:our bLNPs specifically targeting PTP1B has been uniquely desi
Slide 27: PTP1B in the CNS only restores insulin & leptin sensitivity
PTP1B in the CNS only, restores both insulin & leptin sensitivity* PTP1B -/- in leptin-receptor expressing neurons Neuron-specific PTP1B -/- leads to leads to CNS • Decrease in body weight & fat mass • Leptin hypersensitivity • Increased activity and energy expenditure • Decrease in body weight & fa
Slide 28: Central PTP1B targeting exhibits most profound global effects
Central (brain) PTP1B targeting exhibits the most profound global effects on both energy balance & glucose homeostasis* • Global neuronal deletion of PTP1B dramatically reduces obesity and enhances leptin + insulin sensitivity % • Various areas of the brain involved in energy balance (hypothalamus,
Slide 29: Targeting PTP1B in peripheral tissue vs CNS
Targeting PTP1B in peripheral tissue vs CNS – key differences Studies correlating lowered PTP1B levels to metabolic impact in liver, muscle and adipose tissue highlight: For the Periphery • In liver – this improves insulin signalling & responsiveness, reduces gluconeogenesis & lipogenesis, alleviate
Slide 30: Mice lacking neuronal PTP1B are resistant to diet-induced obesity
Mice lacking neuronal PTP 1 B are resistant to diet-induced obesity and are protected from developing leptin resistance WT WT PTP1B+/ - PTP1B+/ - PTP1B- / - PTP1B- / - WT PTP1B- / - WT PTP1B- / - Conclusion of the study: “for effective obesity treatment and optimal therapy for type 2 diabetes, PTP1B
Slide 31: PoC for PTP1B Targeting In Vivo: antisense in diabetic mice
PoC for PTP1B Targeting In Vivo: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice Zinker B, Rondinone CM et al. PNAS, August 2002, 99(17): 11357-11362 IV Delivery biogenetherapeutics. com 31
Slide 32: PoC for PTP1B Targeting In Vivo: non-obese monkeys
PoC for PTP1B Targeting In Vivo: Antisense oligonucleotides suppresses Protein Tyrosine Phosphatase-1B and modulates key regulators of glucose and fat metabolism in non-obese monkeys IV Delivery Swarwick M et al. Endocrinology, April 2009, 150(4):1670–1679 biogenetherapeutics. com 32
Slide 33: PoC for PTP1B Targeting In Vivo: insulin sensitivity in monkeys
PoC for PTP1B Targeting In Vivo: Inhibition of Protein Tyrosine Phosphatase- 1B with antisense oligonucleotides improves insulin sensitivity in monkeys in a dose-dependent manner IV Delivery Insulin Resistant Rhesus Macaques Normal Non-Obese Rhesus Macaques Swarwick M et al. Endocrinology, April 200
Slide 34: Comparison of targets - GLP1RAs & PTP1B
Comparison of targets - GLP1RAs & PTP1B Mechanism of action: GLP1RAs - increase insulin secretion (pancreas), delay gastric emptying (direct GI effects) and reduce appetite (CNS) PTP1B inhibition - enhances insulin and leptin receptor signalling in brain, liver, muscle & adipose tissue, targeting th
Slide 35: PTP1B: Obesity, T2D AND BEYOND!
PTP1B : Obesity, T2D AND BEYOND! PTP1B inhibition reduces neuroinflammation and fronto-temporal dementia in animal models displaying potential for the treatment of Alzheimer’s Disease Source: Pharmacological PTP1B inhibition rescues motor learning, neuroinflammation, and hyperglycaemia in a mouse mo
Slide 36: Gene Targeting Strategy with Smart-siRNAs against the PTPN1 gene
Gene Targeting Strategy with BioGene’s ‘Smart-siRNAs’ against the PTPN1 gene The PTPN1 gene comprises 10 exons, each potential targets for siRNA: 1 2 3 4 5 6 7 8 9 10 63bp 91bp 101bp 99bp 138bp 210bp 162bp 224bp 196bp 24bp 01 02 03 Successfully engineered siRNA’s against both siRNA sequences were se
Slide 37: Potent Gene Silencing Confirmed with bLNPs
Potent Gene Silencing Confirmed bLNP-1 withBioGene’s BioresponsiveLNPs (bLNPs) • bLNPs possess the unique bioresponsive ‘gene- releasing’ linker (US Patent #11,566,044 – granted 31/Mar/23). • UQP12 & UQP15 (top and bottom graphs) represent select bLNP-2 Smart-siRNAs showing potent gene silencing whe
Slide 38: Planned Diabetes and Obesity Preclinical Study
Planned Diabetes and Location: The University of Queensland, Brisbane 01 • Extensive expertise with Sol-Gel engineering, bLNP Obesity formulation & preclinical models of obesity and diabetes Preclinical Study Research Team Led by BioGene’s Chief Scientific 02 Officer & Co-Founder, Dr. Harry Parekh.
Slide 39: Revenue and Corporate Strategy
Revenueand CorporateStrategy Platform Acquisition and Direct Listing Licensing Partnerships on NASDAQ Potential b io ge nethe rap eutics . ccom biogenetherapeutics. om 39
Slide 40: Global Collaborators
Global Collaborators b io ge nethe rap eutics . c om 40
Slide 41: Thank you
Thank you biogenetherapeutics. com 41
BioGene Therapeutics — Investor Presentation (June 2026) on 6ix